These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36335684)

  • 1. Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+: The pragmatic, multicenter, placebo-controlled GLORIA trial.
    Hartman L; El Alili M; Cutolo M; Opris D; Da Silva J; Szekanecz Z; Buttgereit F; Masaryk P; Bos R; Kok MR; Paolino S; Coupé V; Lems WF; Boers M;
    Semin Arthritis Rheum; 2022 Dec; 57():152109. PubMed ID: 36335684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial.
    Hartman L; Rasch LA; Klausch T; Bijlsma HWJ; Christensen R; Smulders YM; Ralston SH; Buttgereit F; Cutolo M; Da Silva JAP; Opris D; Rovenský J; Szamosi S; Middelink LM; Lems WF; Boers M
    Trials; 2018 Jan; 19(1):67. PubMed ID: 29370811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations.
    Hewlett S; Almeida C; Ambler N; Blair PS; Choy E; Dures E; Hammond A; Hollingworth W; Kadir B; Kirwan J; Plummer Z; Rooke C; Thorn J; Turner N; Pollock J
    Health Technol Assess; 2019 Oct; 23(57):1-130. PubMed ID: 31601357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.
    Boers M; Hartman L; Opris-Belinski D; Bos R; Kok MR; Da Silva JA; Griep EN; Klaasen R; Allaart CF; Baudoin P; Raterman HG; Szekanecz Z; Buttgereit F; Masaryk P; Klausch LT; Paolino S; Schilder AM; Lems WF; Cutolo M;
    Ann Rheum Dis; 2022 Jul; 81(7):925-936. PubMed ID: 35641125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in body weight and body composition in patients with active rheumatoid arthritis aged 65+ treated with 2-year low-dose add-on prednisolone in the randomised double-blind placebo-controlled GLORIA trial.
    Güler-Yüksel M; Kuijper M; Bos R; Molenaar E; Emmering J; Eshuis S; Human A; Reimann F; Boers M; Kok MR
    RMD Open; 2023 Jun; 9(2):. PubMed ID: 37349120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
    Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
    Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial.
    Almayali AAH; Boers M; Hartman L; Opris D; Bos R; Kok MR; Da Silva JA; Griep E; Klaasen R; Allaart CF; Baudoin P; Raterman HG; Szekanecz Z; Buttgereit F; Masaryk P; Lems W; Smulders Y; Cutolo M; Ter Wee MM
    Ann Rheum Dis; 2023 Oct; 82(10):1307-1314. PubMed ID: 37541762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial.
    Pazmino S; Boonen A; Stouten V; De Cock D; Joly J; Van der Elst K; Westhovens R; Verschueren P
    Ann Rheum Dis; 2020 May; 79(5):556-565. PubMed ID: 32241795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
    Chalmers JR; Wojnarowska F; Kirtschig G; Mason J; Childs M; Whitham D; Harman K; Chapman A; Walton S; Schmidt E; Godec TR; Nunn AJ; Williams HC
    Health Technol Assess; 2017 Mar; 21(10):1-90. PubMed ID: 28406394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daily low-dose prednisolone to prevent relapse of steroid-sensitive nephrotic syndrome in children with an upper respiratory tract infection: PREDNOS2 RCT.
    Christian MT; Webb NJ; Woolley RL; Afentou N; Mehta S; Frew E; Brettell EA; Khan AR; Milford DV; Bockenhauer D; Saleem MA; Hall AS; Koziell A; Maxwell H; Hegde S; Finlay ER; Gilbert RD; Jones C; McKeever K; Cook W; Ives N
    Health Technol Assess; 2022 Jan; 26(3):1-94. PubMed ID: 35060851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis.
    Wailoo A; Hernández Alava M; Scott IC; Ibrahim F; Scott DL
    Rheumatology (Oxford); 2014 Oct; 53(10):1773-7. PubMed ID: 24771112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Prednisolone to Treat Bell Palsy in Children: An Economic Evaluation Alongside a Randomized Controlled Trial.
    Xiong X; Huang L; Herd DW; Borland ML; Davidson A; Hearps S; Mackay MT; Lee KJ; Dalziel SR; Dalziel K; Cheek JA; Babl FE
    Neurology; 2023 Jun; 100(24):e2432-e2441. PubMed ID: 37072220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.
    Lee MY; Park SK; Park SY; Byun JH; Lee SM; Ko SK; Lee EK
    Clin Ther; 2015 Aug; 37(8):1662-76.e2. PubMed ID: 26243076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
    Webb NJ; Woolley RL; Lambe T; Frew E; Brettell EA; Barsoum EN; Trompeter RS; Cummins C; Wheatley K; Ives NJ
    Health Technol Assess; 2019 May; 23(26):1-108. PubMed ID: 31156083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy.
    McCrone P; Chisholm D; Knapp M; Hughes R; Comi G; Dalakas MC; Illa I; Kilindireas C; Nobile-Orazio E; Swan A; Van den Bergh P; Willison HJ;
    Eur J Neurol; 2003 Nov; 10(6):687-94. PubMed ID: 14641514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis.
    Symmons D; Tricker K; Roberts C; Davies L; Dawes P; Scott DL
    Health Technol Assess; 2005 Sep; 9(34):iii-iv, ix-x, 1-78. PubMed ID: 16153351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The outcome and cost-effectiveness of nurse-led care in people with rheumatoid arthritis: a multicentre randomised controlled trial.
    Ndosi M; Lewis M; Hale C; Quinn H; Ryan S; Emery P; Bird H; Hill J
    Ann Rheum Dis; 2014 Nov; 73(11):1975-82. PubMed ID: 23982436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of a brief education, self-management and upper limb exercise training in people with rheumatoid arthritis (EXTRA) programme: a trial-based analysis.
    Manning VL; Kaambwa B; Ratcliffe J; Scott DL; Choy E; Hurley MV; Bearne LM
    Rheumatology (Oxford); 2015 Feb; 54(2):302-9. PubMed ID: 25173349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.